The Institute for Clinical and Economic Review has released a report on lecanemab, an anti-amyloid monoclonal antibody approved by the FDA for the treatment of Alzheimer’s disease. The report found that while lecanemab showed a statistically significant 27% slowing of cognitive decline compared to placebo, there are concerns about the potential harm from amyloid-related imaging abnormalities. The report also found that lecanemab’s annual price of $26,500 exceeds commonly used cost-effectiveness thresholds, and recommended efforts to achieve affordability and access. The report calls for all stakeholders to address health inequities in introducing new treatments for Alzheimer’s disease, and for manufacturers to follow the example of the lecanemab manufacturer in sharing transparent pricing justifications and releasing all patient-level data.
📊 The burden of hearing loss in Africa is rising, with projections estimating that 54 million people will be affected by 2030 if no action is taken. This alarming increase highlights the urgent need for policy advocacy and improved access to ear and hearing care services.
Discover the key findings from the WHO report and the steps needed to address this pressing issue.
#SyenzaNews #HearingHealth #PublicHealth
📊 Turkey’s pharmaceutical sector is on the rise! The latest “August 2024 Foreign Trade Analysis” offers a deep dive into the performance and dynamics of foreign trade, showcasing a 3.5% increase in total exports. 🌍 Discover the insights and market trends shaping the future of the pharmaceutical industry in Türkiye.
#SyenzaNews #PharmaceuticalIndustry #TradeAnalysis #Türkiye
🌍 Celebrating a decade of **ethical collaboration** among healthcare leaders! Health Policy Watch explores the groundbreaking achievements and future directions of this international consensus. By uniting efforts, we can tackle complex health challenges more effectively.
Read more about the role of ethical collaboration in shaping global health outcomes!
#SyenzaNews #GlobalHealth #EthicalCollaboration
SPEAK WITH US
CORRESPONDENCE ADDRESS
1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA
WRITE US
JOIN NEWSLETTER
